argenx NV ADR (ARGX)vsCASI Pharmaceuticals Inc (CASI)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $56.45B
CASI
CASI Pharmaceuticals Inc
$0.21
0.00%
HEALTHCARE · Cap: $3.21M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 17565% more annual revenue ($4.74B vs $26.85M). ARGX leads profitability with a 31.4% profit margin vs -184.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CASI
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$891.32
$1313.01 discount
Intrinsic value data unavailable for CASI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
No standout strengths identified
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 188.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -1095.0% — below average capital efficiency
Revenue declined 60.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : CASI
CASI has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Bear Case : CASI
The primary concerns for CASI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CASI is a turnaround play — different risk/reward profiles.
CASI carries more volatility with a beta of 0.89 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 24/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
CASI Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · China
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?